

THE VALUE OF POPULATION-BASED STUDIES AND THEIR ASSOCIATED BIOBANKS IN STUDYING LONG TERM EXPOSURE EFFECTS

Anna Beckmeyer-Borówko, PhD, MPH, MBA


on Behalf of

Prof. Dr. Nicole Probst-Hensch's Group

Challenges when studying associations between exposure and outcomes with long latencies

Study Designs

Observational Studies



Increasing Strength of Scientific Evidence

- ☐ < Confounding Factors
- ☐ Decreasing Biases
- ☐ Temporality

Strengths of Prospective Population-Based Cohort Studies

- Results can be generalizable to the entire population
- Incidence of the disease
 - ☐ Relative Risks
- Temporal relationship
- Possibility to study multiple exposures and outcomes
 - ☐ Multifactorial diseases

THE FAMILY CIRCUS




"I wish they didn't turn on that seatbelt sign so much! Every time they do, it gets bumpy."

Biobanks

- Repository for biologic materials
 - Whole blood
 - Saliva
 - Urine
 - DNA
- Biologic markers
 - Of exposure
 - For susceptibility
 - Of early disease
- Help quantify the occurrence of the disease including gene-environment interactions



Gene – Environment Interaction



Challenges

In Measuring Exposures Associated With Long Latency Diseases

1. Cumulative exposures
2. Recall bias, incomplete measurements, inaccurate data
3. Critical window
 - Easier to identify for acute or moderately short exposures
4. Multiple exposures



Strengths

of Cohort Studies and Biobanks in Measuring Exposure Associated with Long Latency Diseases

1. Cumulative exposures
2. Recall bias, incomplete measurements, inaccurate data
3. Critical window
 - Easier to identify for acute or moderately short exposures
4. Multiple exposures

1. Prospective AND Longitudinal measurements, active follow-ups
2. Triangulation of data
 - Questionnaires, biomarkers, national exposure data

Longitudinal measurements of same participants



SAPALDIA

26 Year Old Prospective, Longitudinal and
Population-Based Cohort Study of the Swiss TPH

SAPALDIA

Swiss Study on Air Pollution and Lung Disease in Adults

1. SAPALDIA 1: 1991, $n = 9651$
2. SAPALDIA 2: 2002, $n = 8047$
3. SAPALDIA 3: 2010, $n = 6139$
4. SAPALDIA 4: 2017, $n = ?$



SAPALDIA

- Prospective population based-cohort study
 - Longitudinal study with 4 time-points
 - Same participants
 - 26 years of follow-up
 - High attrition
- Data obtained through
 - Questionnaires
 - Phone interviews
 - In person assessment
- Biobank
 - Saliva, urine, stool
 - Serum, plasma, whole blood
 - DNA



SAPALDIA Data

NOT PERSONALLY MODIFIABLE EXPOSURES

genetics
gender
noise exposure
air pollution
socioeconomic status

EFFECT MODIFICATION/ LIFE STYLE

- blood markers
- smoking
- nutrition
- physical activity
- occupation
- obesity
- reproductive/
hormonal factors
- social network

FUNCTIONAL PARAMETERS

Quality of life

lung
function
Bronchial
reagibility

Cardiovasc.
parameters:
-BP
-HRV
-PWV
-CMT

parameters
of aging

DISEASES/ DEATH

Respiratory Diseases

- COPD
- Asthma
- Lung cancer

Cardiovascular Diseases


- Ischemic HD
- Heart failure

Diabetes

Other Chronic Diseases

Strengths of SAPALDIA: Exposure Assessment

1. Prospective assessment of exposures in various geographic areas
2. Cumulative exposures
3. Broad and rich data on risk factors, effect modifiers
4. Broad adult age range
5. Incidence of chronic diseases and presence of comorbidities
6. Biologic markers of exposure



Strengths of SAPALDIA: Analytical Possibilities

1. Cross-sectional analyses for each time-point
2. Longitudinal Analyses
3. Prediction Analyses






Epigenome - Wide Association Study on Lung Function

The ALEC project

AGEING LUNGS IN EUROPEAN COHORTS (ALEC Study)




[PROGRAMME](#)[PARTNERS](#)[PUBLIC](#)[FUNDING](#)[RESULTS](#)[CONTACT](#)[NEWS](#)

Goal: To generate a predictive risk score for COPD

Prof. Dr. Nicole Probst-Hensch has the lead on the work package 5

- How genetic and epigenetic changes impact lung function

DNAm – an Epigenetic Mechanism



Smoking and Lung Function

- **Aim:** To identify lung function methylation signals related to smoking in the three ALEC population-based cohorts, ECRHS, NFBC, SAPALDIA.
- Smoking is the **STRONGEST & MODIFIABLE** predictor of poor lung health
- **Goal:** To understand Smoking Mechanisms in Lung Disease

DNAm and Lung Function

Smoking-related DNAm patterns have the potential for understanding of biological mechanisms of long-term exposure to tobacco smoke

1. DNAm sites shown to be associated with smoking exposure AND also with lung disease (Zhu et al., Gao et al. 2015)
2. Different patterns of DNAm reported for active smokers, passive smoking exposure (in utero), never smokers (Joehanes et al. 2016)

DNAm and Lung Function con't

Smoking-related DNAm patterns have the potential for improved assessment of long-term exposure to tobacco smoke

4. Methylation levels of CpGs can but do not always return toward that of never smokers after years of smoking cessation (Joezhanes et al. 2016, Ambatipudi et al (2016))
 - The CpGs whose methylation did not return to baseline levels may serve as markers for follow-up of former smokers for secondary cancer prevention
5. Enrichment for CPGs in genes related to respiratory lung phenotype was found (Joezhanes et al. 2016)





Fig. 3 Effect sizes of smoking-induced methylation for current smokers and former smokers compared with non-smokers. *Chr* chromosome position, used the publicly available data of Zeilinger et al. (median beta values) [6]

Trajectories of cytosine–phosphate–guanine (CpG) sites that did not return to never-smoker levels within 30 years after cessation.



Joehanes et al. 2016

Conclusion

Biomarkers (genetic and DNAm) improve the assessment of exposures related to outcomes with long latencies

1. Appropriate assessment of exposures
2. Not ready in most cases for individual risk prediction
3. Important research instruments to improve causal understanding of modifiable risk factors
4. Point to mechanism of action mediating the smoke effect
5. Could be used in the future in personalized medicine

Acknowledgments

Prof. Dr. Nicole Probst-Hensch - PI of SAPALDIA

Dr. Medea Imboden – Senior SAPALDIA scientist

SAPALDIA participants

Funding Agencies - The Swiss National Science Foundation

Acknowledgments con't

Scientific Team at Coordinating Centers

M Adam, I Aguilera, S Brunner, D Carballo, S Caviezel, I Curjuric, A Di Pascale, J Dratva, R Ducret, E Dupuis Lozeron, M Eeftens, I Eze, E Fischer, M Foraster, M Germond, L Grize, S Hansen, A Hensel, M Imboden, A Ineichen, A Jeong, D Keidel, A Kumar, N Maire, A Mehta, R Meier, E Schaffner, T Schikowski, M Tsai

Local Fieldworkers

Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Bürli, C Dahler, N Oertli, I Harreh, F Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier, J Rakic, U Schafroth, A Walder.

THE VALUE OF POPULATION-BASED STUDIES AND THEIR ASSOCIATED BIOBANKS IN STUDYING LONG TERM EXPOSURE EFFECTS

Anna Beckmeyer-Borówko, PhD, MPH, MBA

on Behalf of

Prof. Dr. Nicole Probst-Hensch's Group